EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion

Amber Meurs, Klevis Ndoj, Marlene van den Berg, Goran Marinković, Matteo Tantucci, Tineke Veenendaal, Jan Albert Kuivenhoven, Judith Klumperman, Noam Zelcer iD

Cardiovascular Research · 2024

DOI: 10.1093/cvr/cvae121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cardiovascular Research, 2024. Verfasst von Amber Meurs und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism and Amsterdam Cardiovascular Sciences, Univers…. Hauptthemen laut MEDLINE: Hepatocytes, Lipoproteins, VLDL, Gene Editing, Apolipoprotein B-100. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, EndoConnect, ZonMw.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Apolipoprotein B (APOB)-containing very LDL (VLDL) production, secretion, and clearance by hepatocytes is a central determinant of hepatic and circulating lipid levels. Impairment of any of the aforementioned processes is associated with the development of multiple diseases. Despite the discovery of genes and processes that govern hepatic VLDL metabolism, our understanding of the different mechanistic steps involved is far from complete. An impediment to these studies is the lack of tractable hepatocyte-based systems to interrogate and follow APOB in cells, which the current study addresses. Methods and results To facilitate the cellular study of VLDL metabolism, we generated human hepatic HepG2 and Huh-7 cell lines in which CRISPR/Cas9-based genome engineering was used to introduce the fluorescent protein mNeonGreen into the APOB gene locus. This results in the production of APOB100-mNeon that localizes predominantly to the endoplasmic reticulum (ER) and Golgi by immunofluorescence and electron microscopy imaging. The production and secretion of APOB100-mNeon can be quantitatively followed in medium over time and results in the production of lipoproteins that are taken up via the LDL receptor pathway. Importantly, the production and secretion of APOB-mNeon is sensitive to established pharmacological and physiological treatments and to genetic modifiers known to influence VLDL production in humans. As a showcase, we used HepG2-APOBmNeon cells to interrogate ER-associated degradation of APOB. The use of a dedicated sgRNA library targeting all established membrane-associated ER-resident E3 ubiquitin ligases led to the identification of SYNV1 as the E3 responsible for the degradation of poorly lipidated APOB in HepG2 cells.

Conclusions

In summary, the engineered cells reported here allow the study of hepatic VLDL assembly and secretion and facilitate spatiotemporal interrogation induced by pharmacologic and genetic perturbations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HepatocytesLipoproteins, VLDLGene EditingApolipoprotein B-100CRISPR-Cas SystemsHumansHep G2 CellsEndoplasmic ReticulumGolgi ApparatusTime FactorsReceptors, LDL

Stichwörter der Autor:innen

APOBERADHRD1HepatocytesLipoprotein metabolismMASLDSYVN1VLDL

Substanzen

Lipoproteins, VLDLApolipoprotein B-100APOB protein, humanReceptors, LDLLDLR protein, human

Autor:innen und Institutionen

  • Department of Medical Biochemistry, Amsterdam UMC, Amsterdam Gastroenterology Endocrinology Metabolism and Amsterdam Cardiovascular Sciences, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.
  • Center for Molecular Medicine-Cell Biology, University Medical Center Utrecht, University of Utrecht, Heidelberglaan 100, 3584CX Utrecht, The Netherlands.
  • Department of Pediatrics, University Medical Center Groningen, University of Groningen, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands.

ORCID-Profile: Noam Zelcer

Förderung

  • European Union
  • EndoConnect
  • ZonMw
  • Dutch Research Council
  • Dutch Heart Foundation
  • Netherlands Organization for Scientific Research
  • GENESIS

Zitieren

APA

Meurs, A., Ndoj, K., van den Berg, M., Marinković, G., Tantucci, M., Veenendaal, T., Kuivenhoven, J. A., Klumperman, J., & Zelcer, N. (2024). A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion. Cardiovascular Research. https://doi.org/10.1093/cvr/cvae121

Vancouver

Meurs A, Ndoj K, van den Berg M, Marinković G, Tantucci M, Veenendaal T, et al. A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion. Cardiovascular Research. 2024. doi:10.1093/cvr/cvae121

BibTeX
@article{Meurs2024,
  author = {Meurs, Amber and Ndoj, Klevis and van den Berg, Marlene and Marinković, Goran and Tantucci, Matteo and Veenendaal, Tineke and Kuivenhoven, Jan Albert and Klumperman, Judith and Zelcer, Noam},
  title = {A suite of genome-engineered hepatic cells provides novel insights into the spatiotemporal metabolism of apolipoprotein B and apolipoprotein B–containing lipoprotein secretion},
  journal = {Cardiovascular Research},
  year = {2024},
  doi = {10.1093/cvr/cvae121}
}
Kostenlos starten →